Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 3:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: EMBEDA (morphine sulfate / naltrexone hydrochloride) Clear all

Conditions: Opioid-Related Disorders, Opioid Withdrawal
Interventions: Buprenorphine/naloxone, Morphine, Tramadol; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Chronic Noncancer Pain
Interventions: oxycodone HCl and naltrexone HCl extended-release capsules; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 32
States / cities: DeLand, Florida • Jacksonville, Florida • Jupiter, Florida + 27 more

Conditions: Pain
Interventions: Oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Moderate-severe Pain
Interventions: ALO-02; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 16
States / cities: Lancaster, California • Los Angeles, California • Sacramento, California + 4 more

Conditions: Pain
Interventions: Oxymorphone; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Osteoarthritis, Chronic Pain
Interventions: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release), Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years and older
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 81
States / cities: Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 69 more

Conditions: Pain
Interventions: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 58
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 48 more

Conditions: Management of Moderate to Severe Pain
Interventions: ALO-02, Naltrexone block, OxyContin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Pain, Low Back Pain, Analgesia
Interventions: ALO-02, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 52
States / cities: Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 38 more

Conditions: Chronic Pain
Interventions: EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush, EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Opioid-Related Disorders
Interventions: oxycodone and naltrexone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Oxycodone, Naltrexone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: HIV Infection, Opioid-use Disorder, Cardiovascular Diseases
Interventions: buprenorphine/naloxone, Methadone, Naltrexone Injection, Heroin; Drug
Lead sponsor: MetroHealth Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Cleveland, Ohio

Conditions: Healthy
Interventions: Oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Chronic Disease, Pain
Interventions: morphine sulfate and naltrexone hydrochloride (EMBEDA); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years and older
Enrollment: 684 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 166
States / cities: Adamsville, Alabama • Birmingham, Alabama • Huntsville, Alabama + 144 more

Conditions: Healthy
Interventions: PF614, Oxycodone extended-release, Naltrexone Hydrochloride; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy
Interventions: Oxycodone controlled-release test formulation, Immediate-release reference drug; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: Placebo, Oxycodone + Naltrexone, Oxycodone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Nondependent Opioid Abuse, Episodic
Interventions: Placebo, MS Contin (morphine sulfate, controlled release), EMBEDA (morphine sulfate / naltrexone hydrochloride); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: Oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 2
States / cities: Overland Park, Kansas

Conditions: Withdrawal Symptoms
Interventions: Oxycodone/Naltrexone Capsules, Oxycodone, Placebo; Drug
Lead sponsor: Elite Laboratories, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Oxycodone; Drug
Lead sponsor: Pain Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Volunteers
Interventions: PF614, Naltrexone Hydrochloride, OxyContin; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

Comparison of Three Opioid Detoxification Treatment Regimens

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers

Food Effect And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers

Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain

Bioequivalency Study of Oxymorphone Hydrochloride 10 mg Tablets Under Fasted Conditions

A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

Pharmacokinetics Study of ALO-02 and OxyContin

A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain

Safety Study to Assess Opiate Withdrawal Signs and Symptoms in Opioid Dependent Patients

Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse

Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers

Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV

Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions

Conversion to Embeda With Rescue Trial

Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)

A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers

A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users

Abuse Potential of Orally Administered Crushed Embeda Compared to Crushed Controlled-Release Morphine and Placebo in Non-Dependent Recreational Opioid Users

Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers

A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects

Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers

Evaluation of Oral PF614 Relative to OxyContin (PF614-102)